{"Title": "FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements", "Year": 2020, "Source": "Future Oncol.", "Volume": "16", "Issue": 30, "Art.No": null, "PageStart": 2385, "PageEnd": 2399, "CitedBy": 3, "DOI": "10.2217/fon-2020-0429", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85094684730&origin=inward", "Abstract": "\u00a9 2020 Tanios Bekaii-Saab.FGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA. Pemigatinib, a selective, potent, oral inhibitor of FGFR1-3, has demonstrated efficacy and safety in a Phase II study of patients with previously treated locally advanced/metastatic CCA harboring FGFR2 fusions/rearrangements. We describe the study design of FIGHT-302, an open-label, randomized, active-controlled, multicenter, global, Phase III study comparing the efficacy and safety of first-line pemigatinib versus gemcitabine plus cisplatin in patients with advanced CCA with FGFR2 rearrangements (NCT03656536). The primary end point is progression-free survival; secondary end points are objective response rate, overall survival, duration of response, disease control rate, safety and quality of life.", "AuthorKeywords": ["cholangiocarcinoma", "FGFR", "INCB054828", "pemigatinib"], "IndexKeywords": null, "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85094684730", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"8643412400": {"Name": "Bekaii-Saab T.S.", "AuthorID": "8643412400", "AffiliationID": "60026952", "AffiliationName": "Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic"}, "57202377479": {"Name": "Borad M.J.", "AuthorID": "57202377479", "AffiliationID": "60026952", "AffiliationName": "Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic"}, "7101953217": {"Name": "Valle J.W.", "AuthorID": "7101953217", "AffiliationID": "60003771, 60028784", "AffiliationName": "Division of Cancer Sciences, University of Manchester, Department of Medical Oncology, Christie Hospital Nhs Foundation Trust, University of Manchester"}, "57212668756": {"Name": "Van Cutsem E.", "AuthorID": "57212668756", "AffiliationID": "60025063", "AffiliationName": "Department of Oncology, University of Leuven"}, "6602480388": {"Name": "Rimassa L.", "AuthorID": "6602480388", "AffiliationID": "60107210", "AffiliationName": "Department of Biomedical Sciences, Humanitas University"}, "56667172600": {"Name": "Furuse J.", "AuthorID": "56667172600", "AffiliationID": "60020028", "AffiliationName": "Department of Medical Oncology, Kyorin University"}, "6603709682": {"Name": "Ioka T.", "AuthorID": "6603709682", "AffiliationID": "60138477", "AffiliationName": "Department of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute"}, "6508252700": {"Name": "Melisi D.", "AuthorID": "6508252700", "AffiliationID": "60032256", "AffiliationName": "Department of Medicine, University of Verona"}, "57219529342": {"Name": "MacArulla T.", "AuthorID": "57219529342", "AffiliationID": "60110094, 60012486", "AffiliationName": "Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology"}, "7003634798": {"Name": "Bridgewater J.", "AuthorID": "7003634798", "AffiliationID": "60109234, 60022148", "AffiliationName": "Research Department of Oncology, Ucl Cancer Institute, University College London"}, "6701461568": {"Name": "Wasan H.", "AuthorID": "6701461568", "AffiliationID": "60020416, 60111785", "AffiliationName": "Department of Medical Oncology, Hammersmith Hospital, Imperial College Health Care Trust"}, "8660213800": {"Name": "Abou-Alfa G.K.", "AuthorID": "8660213800", "AffiliationID": "60007997, 60007776", "AffiliationName": "Department of Medicine, Weill Medical College, Cornell University"}, "57219674291": {"Name": "Jiang P.", "AuthorID": "57219674291", "AffiliationID": "60018260", "AffiliationName": "Incyte Corporation"}, "36340209600": {"Name": "Lihou C.F.", "AuthorID": "36340209600", "AffiliationID": "60018260", "AffiliationName": "Incyte Corporation"}, "57215642078": {"Name": "Zhen H.", "AuthorID": "57215642078", "AffiliationID": "60018260", "AffiliationName": "Incyte Corporation"}, "6507816451": {"Name": "Asatiani E.", "AuthorID": "6507816451", "AffiliationID": "125291197", "AffiliationName": "Incyte Biosciences International S\u00e0rl"}, "57215647544": {"Name": "F\u00e9liz L.", "AuthorID": "57215647544", "AffiliationID": "125291197", "AffiliationName": "Incyte Biosciences International S\u00e0rl"}, "7102618692": {"Name": "Vogel A.", "AuthorID": "7102618692", "AffiliationID": "60024052", "AffiliationName": "Department of Gastroenterology Hepatology and Endocrinology, Hannover Medical School"}}}